Neuromodulation may help selected patients with chronic nerve-related, pelvic, spine-related, or complex pain when conservative treatments have not provided enough relief.
Learn how Dr. Siefferman explains neuromodulation, how it works to interrupt pain signals, and which patients may benefit from these advanced pain management therapies.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
Hi, I’m Dr. Jason Siefferman, medical director of Manhattan Pain Medicine and interventional pain specialist. When we have a patient with complex chronic pain and no other modalities have been effective, we start to think about neuromodulation. We use electricity to interrupt pain signals going to the brain. And neuromodulation may be used at a variety of fronts. We can do peripheral nerve modulation for nerves outside the spine.
This may be as simple as a TENS unit or as complex as an implanted peripheral nerve stimulator. We may use spinal cord stimulation, and spinal cord stimulation comes in a few different varieties. The first is dorsal column stimulation, which is the first original kind of spinal cord stimulator.
This is where we place electrodes in the epidural space along the spine, and we place them in a way that we can control signaling from some part of the body to the brain. We do these as a trial. We see if it’s helpful before we proceed with any implant. The other type of spinal cord stimulation is called dorsal root ganglion or DRG stimulation. This is where we use a stimulator, a lead that goes directly to the nerve as it exits the spine.
This allows us to provide very focused neuromodulation to a very specific nerve. And we will often use these for sequential nerves in difficult cases for intercostal neuralgia or complex regional pain syndrome, or we’ll even use it for pelvic pain. If there is a difficult situation that has not been adequately managed and there’s not a better treatment option, we will discuss neuromodulation and consider a trial of a spinal cord stimulator or peripheral nerve stimulator to see if it is an option for you. Then of course, if it is, we can talk about permanent implantation.
Neuromodulation is an advanced pain treatment category that uses targeted electrical stimulation to change how pain signals are processed by the nervous system. In pain medicine, neuromodulation may include spinal cord stimulation, peripheral nerve stimulation, and dorsal root ganglion stimulation.
At Manhattan Pain Medicine, neuromodulation NYC care begins with diagnosis-first evaluation. The goal is to determine whether pain is coming from a specific nerve, nerve root, spinal pathway, pelvic nerve, peripheral nerve, or complex pain pathway before considering a stimulator-based treatment. Neuromodulation is not a cure for chronic pain, and it is not appropriate for every patient. It is usually considered only after less invasive treatments have not provided enough relief and the pain pattern appears appropriate for a trial-based neuromodulation pathway.
MPM specialists evaluate whether neuromodulation may be appropriate by reviewing the patient’s diagnosis, pain distribution, prior treatment response, nerve block results, imaging, medication history, pelvic pain history, neurological symptoms, functional goals, psychological readiness, safety factors, and device-related considerations. Neuromodulation may be considered for selected patients with chronic nerve pain, pelvic pain, pudendal neuralgia, pelvic dystonia, PGAD-related symptoms, spine-related pain, or complex chronic pain when the pain pathway is clinically appropriate.
MPM evaluates whether spinal cord stimulation, peripheral nerve stimulation, dorsal root ganglion stimulation, continued nerve blocks, nerve hydrodissection, medication management, pain psychology, pelvic floor therapy, rehabilitation, surgery, or another pathway is more appropriate.
Patients often search for neuromodulation in Manhattan when they have chronic pain that has not improved enough with medication, injections, physical therapy, pelvic floor therapy, pain psychology, nerve blocks, or prior procedures. Many are trying to understand whether spinal cord stimulation, peripheral nerve stimulation, or dorsal root ganglion stimulation may be appropriate.
MPM approaches neuromodulation as a selective treatment pathway, not a device-first solution. The most important step is identifying the pain pathway and matching the treatment to the patient’s symptoms, anatomy, prior response, safety profile, and goals. A neuromodulation trial is often used before permanent implantation to help determine whether stimulation provides meaningful benefit. The response to the trial helps guide next steps.
Neuromodulation fits within MPM’s Pelvic Pain, Complex Chronic Pain, Headache, and Musculoskeletal issues expertise because persistent pain often involves overlapping nerve, spine, pelvic, muscular, and nervous system pathways.
A patient may have pudendal neuralgia, pelvic floor dysfunction, pelvic dystonia, PGAD-related symptoms, spine-related nerve pain, peripheral nerve pain, or complex chronic pain that has not responded to standard care. MPM uses neuromodulation as part of a broader diagnostic and treatment framework. Treatment planning may also include nerve blocks, nerve hydrodissection, sympathetic blocks, pelvic floor therapy, medication management, pain psychology, rehabilitation, spinal cord stimulation, peripheral nerve stimulation, dorsal root ganglion stimulation, or specialty coordination when appropriate.
Before neuromodulation is considered, MPM reviews the diagnosis, pain pattern, prior treatments, imaging, medications, safety factors, psychological readiness, infection risk, insurance requirements, and treatment goals. Patients may need medical clearance, imaging review, psychological screening, and insurance authorization before proceeding.
A neuromodulation trial is typically performed before permanent implantation. During the trial, temporary leads are placed near the target pain pathway and connected to an external device. The goal is to determine whether stimulation meaningfully reduces pain, improves function, and feels tolerable. If the trial is successful, permanent implantation may be discussed. If the trial does not help, the device is not implanted, and MPM reassesses next steps.
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
The best care I've received as a chronic pain patient. I traveled from out of state to visit Manhattan Pain Medicine because I could not find knowledgeable doctors in my hometown for my hypermobility, and Ehlers-Danlos syndrome symptoms and comorbidities. Let me tell you, it was worth every travel e...
I was injured in a bicycle accident over 8 years ago. I’ve suffered throughout the years since my accident with nothing seeming to work. PT, Yoga, lifestyle changes, NOTHNG! I finally made an appointment with Dr Kane and I’m feeling an improvement in my life. I no longer stay up all night in pain, a...
One of the best experiences, if not the best, I have ever had at the doctor’s office. From the front desk to the nurses to the PA assisting the doctor this was a great experience. Dr.Nino actually listened to me and came up with a game plan. Would recommend this practice to as many people as I could...
I have very unique & severe nerve pain from CRPS which has no known specific cure. Dr. Siefferman has a huge tool box, far greater than the other 23 Drs. I have seen. He saved me from jumping off a bridge and continues to help me with both treatments and advice. Dr. S. is in a different league!
After two years of searching and feeling lost and let down, I finally found real help at Manhattan Pain Medicine. With Dr. Siefferman, Adam Rosenberg, Dr. Mikaberidze, and the whole team, I feel heard, supported and understood. Every symptom is being considered and I’m finally getting answers with m...
Why is Dr Dr. Tayyaba Ahmed one of the top pevic Floor specialists - 1- She wants to know a full history of what led the patient to get to this point. 2 - She listens intensley to the patient 3- She does not rush you 4- Extremely skilled at giving pelvic floor injections 5- I thank my luck stars she...
The staff was friendly and helpful. Dr. Siefferman was thoughtful, listened, asked questions and proposed simple safe ways to come to further conclusions regarding my pain and discomfort. The office staff including Dr. Siefferman is responsive even after the initial in-person visit. Very pleased.
Dr. Siefferman is a brilliant provider. While my pain is still a work in progress, Dr Siefferman always gives me options and explains his reasoning behind things. He listens to my feedback and concerns. I never feel rushed; and am grateful he works to meet me where I am. I highly recommend him.
What a great find! They listen to me, I listen to them and the diagnosis is made and a plan developed to develop an approach to treat all of my chronic pain. I wish I could have discovered this type of treatment sooner. This doctor and group give me hope.
Neuromodulation is a treatment approach that uses targeted electrical stimulation to change how pain signals are processed by the nervous system. In pain medicine, neuromodulation may include spinal cord stimulation, peripheral nerve stimulation, and dorsal root ganglion stimulation. At MPM, neuromodulation is considered only after diagnosis-first evaluation of the pain pathway, prior treatments, safety factors, and patient goals.
Neuromodulation works by delivering controlled electrical stimulation to selected nerves or pain pathways. The goal is to reduce how strongly pain signals are perceived or transmitted. It does not remove the original pain generator or cure chronic pain. MPM evaluates whether the patient’s pain pattern appears appropriate for stimulation before recommending a trial.
Neuromodulation may be considered for selected chronic nerve-related, pelvic, spine-related, musculoskeletal, or complex pain patterns that have not improved enough with less invasive care. This may include selected cases of pudendal neuralgia, pelvic pain, pelvic dystonia, PGAD-related symptoms, peripheral nerve pain, spine-related nerve pain, or complex chronic pain. It is not appropriate for every pain condition.
Spinal cord stimulation is a neuromodulation treatment that uses electrical stimulation near the spinal cord to help modulate pain signals. It may be considered for selected chronic pain patterns, often after conservative treatments, injections, or other procedures have not provided enough relief. A trial is usually performed before permanent implantation.
Peripheral nerve stimulation uses electrical stimulation near a specific peripheral nerve that appears to be involved in the pain pattern. It may be considered when pain is localized to a nerve territory and less invasive treatments have not provided enough relief. MPM evaluates the nerve target, prior response to nerve blocks, anatomy, and safety factors before considering this option.
Dorsal root ganglion stimulation, also called DRG stimulation, targets the dorsal root ganglion, a structure involved in transmitting sensory and pain signals. DRG stimulation may be considered for selected focal nerve-related pain patterns. It can be especially relevant when pain is regionally specific and may not be well suited to broader spinal cord stimulation coverage.
Spinal cord stimulation targets broader spinal pain pathways, while dorsal root ganglion stimulation targets specific dorsal root ganglion structures associated with more focused pain regions. The best option depends on the diagnosis, pain location, anatomy, prior treatment response, and goals of care. MPM evaluates these factors before recommending a neuromodulation pathway.
Neuromodulation may be considered for selected pelvic pain patterns when symptoms appear related to nerve, dorsal root ganglion, spinal, or peripheral pain pathways and other treatments have not provided enough relief. Pelvic pain can also come from pelvic floor dysfunction, endometriosis, pudendal neuralgia, pelvic dystonia, orthopedic contributors, inflammatory disease, or central sensitization, so diagnosis-first evaluation is essential.
Neuromodulation may be considered for selected patients with pudendal neuralgia when the pain pattern, prior treatment response, nerve mapping, and safety profile support a stimulation pathway. It is not a first-line treatment and is not guaranteed to help. MPM may use diagnostic blocks, pelvic pain mapping, and treatment history to determine whether peripheral nerve stimulation, DRG stimulation, or another option may be appropriate.
Neuromodulation may be considered in selected complex pelvic pain cases when nerve-related or neuromodulatory pathways appear to contribute to symptoms. Pelvic floor dysfunction and pelvic dystonia often require coordinated care that may include pelvic floor therapy, medication management, trigger point injections, Botox, nerve blocks, pain psychology, or other treatments. Neuromodulation is considered only when the broader clinical picture supports it.
Neuromodulation may be considered for selected PGAD-related symptom patterns when pelvic nerve involvement, dorsal root ganglion involvement, or related pain pathways are suspected and other treatments have not provided enough relief. PGAD-related symptoms can have multiple contributors, so MPM evaluates pelvic nerves, pelvic floor dysfunction, spine-related factors, medication history, psychological distress, and other possible drivers before considering neuromodulation.
A neuromodulation trial is a temporary test period used before permanent implantation. Temporary leads are placed near the target pain pathway and connected to an external device. The patient tracks pain relief, function, comfort, stimulation coverage, and side effects. The trial helps determine whether permanent implantation should be considered.
If the trial provides meaningful pain relief, improved function, tolerable stimulation, and an acceptable safety profile, permanent implantation may be discussed. MPM reviews the trial response, patient goals, risks, insurance requirements, and long-term device considerations before moving forward. A successful trial does not guarantee permanent results, but it provides important decision-making information.
If the trial does not provide meaningful benefit, the temporary leads are removed and permanent implantation is usually not recommended. A failed trial does not mean the pain is not real. It may mean the pain pathway is not appropriate for that form of stimulation, the target needs to be reconsidered, or another treatment approach may be more appropriate.
Risks may include pain flare, infection, bleeding, lead migration, lead fracture, device malfunction, uncomfortable stimulation, loss of benefit, implant site pain, need for reprogramming, battery replacement, revision surgery, nerve irritation, dural puncture headache, rare neurologic injury, incomplete relief, or no relief. MPM reviews risks, alternatives, and long-term device responsibilities before treatment.
Neuromodulation may not be appropriate when the pain generator is unclear, when less invasive treatments have not been fully evaluated, when infection risk is high, when medical clearance is not adequate, when psychological readiness is not appropriate, or when symptoms are better explained by another condition requiring different care. MPM also screens for urgent symptoms before considering a neuromodulation pathway.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
If you are considering neuromodulation in NYC for chronic nerve pain, pelvic pain, pudendal neuralgia, pelvic dystonia, PGAD-related symptoms, spine-related pain, or complex chronic pain, MPM can help determine whether this treatment pathway may be appropriate. Your evaluation will consider your diagnosis, pain pathway, prior care, safety factors, treatment goals, and whether spinal cord stimulation, peripheral nerve stimulation, dorsal root ganglion stimulation, or another option may fit your care plan.
Neuromodulation is an advanced pain treatment category that uses targeted electrical stimulation to change how pain signals are processed by the nervous system. In pain medicine, neuromodulation may include spinal cord stimulation, peripheral nerve stimulation, and dorsal root ganglion stimulation.
At Manhattan Pain Medicine (MPM), neuromodulation NYC care begins with diagnosis-first evaluation. The goal is to understand the pain pathway before considering a stimulator-based treatment. Neuromodulation is not a cure for chronic pain, and it is not appropriate for every patient. It is usually considered only when the diagnosis, symptoms, anatomy, prior treatment response, and safety profile support a trial-based neuromodulation pathway.
Neuromodulation does not remove a damaged nerve, repair a joint, cure a pelvic condition, or eliminate every pain generator. Instead, it uses electrical stimulation to influence the way pain signals are transmitted or perceived. For selected patients, this may reduce pain intensity, improve function, or support a broader pain management plan.
The key question is whether the patient’s pain pattern matches a pathway that can be targeted with stimulation. This is why MPM evaluates the pain location, nerve distribution, spine findings, pelvic symptoms, prior injection response, imaging, medication history, and functional goals before considering neuromodulation.
Spinal cord stimulation targets pain pathways near the spinal cord. It may be considered for selected spine-related, neuropathic, or complex chronic pain patterns.
Peripheral nerve stimulation targets a specific peripheral nerve that appears to be contributing to pain. It may be considered when pain is localized to a nerve territory and diagnostic information supports that target.
Dorsal root ganglion stimulation targets sensory nerve structures involved in pain transmission. It may be considered for selected focal or regional pain patterns, including some pelvic or lower extremity nerve-related pain presentations.
These treatments are not interchangeable. MPM determines which option may be most appropriate based on the diagnosis, anatomy, pain distribution, prior response, and patient goals.
Neuromodulation may be considered for selected patients with chronic pelvic pain, pudendal neuralgia, pelvic floor dysfunction overlap, pelvic dystonia, or PGAD-related symptoms when symptoms appear to involve nerve-related or neuromodulatory pathways and other treatments have not provided enough relief.
Pelvic pain can have multiple overlapping contributors, including pelvic floor muscle dysfunction, pudendal nerve irritation, endometriosis, orthopedic mechanics, spine-related pain, central sensitization, autonomic features, and psychological distress from persistent symptoms. MPM evaluates these contributors before determining whether peripheral nerve stimulation, DRG stimulation, spinal cord stimulation, nerve blocks, pelvic floor therapy, medication management, pain psychology, or another approach may be more appropriate.
A neuromodulation trial is typically performed before permanent implantation. During the trial, temporary leads are placed near the target pain pathway and connected to an external device. The patient then tracks pain relief, function, comfort, stimulation coverage, sleep, activity tolerance, and side effects.
A successful trial usually means the patient experiences meaningful improvement in pain or function with tolerable stimulation and acceptable safety. The exact threshold for success depends on the patient’s goals, diagnosis, functional limitations, and clinical context. If the trial is successful, permanent implantation may be discussed. If the trial does not help, permanent implantation is usually not recommended.
Neuromodulation is usually considered after less invasive treatments have been evaluated. These may include medication management, physical therapy, pelvic floor therapy, nerve blocks, sympathetic blocks, epidural injections, nerve hydrodissection, pain psychology, biofeedback, or other procedures.
Nerve blocks may provide diagnostic information and temporary relief. Injections may reduce inflammation or target specific pain generators. Medication may help reduce nerve sensitivity, inflammation, or associated symptoms. Surgery may be needed when structural disease is the primary driver. Neuromodulation fits into this sequence when the pain pathway appears appropriate for stimulation and other options have not provided enough relief.
Neuromodulation involves a trial, possible implantation, programming, follow-up, and long-term device management. For this reason, psychological readiness and functional goals matter. Chronic pain can affect sleep, mood, trauma responses, fear of movement, and daily function. Pain psychology or behavioral health support may help patients prepare for the process and improve long-term coping and adjustment.
MPM may coordinate neuromodulation planning with medication management, rehabilitation, pelvic floor therapy, pain psychology, imaging review, procedural care, and specialist input when needed.
Neuromodulation may require imaging review, psychological screening, medical clearance, infection risk review, medication review, insurance authorization, and long-term follow-up. Device-related care may include programming adjustments, battery management, monitoring for lead issues, and evaluation if symptoms change.
Risks may include pain flare, infection, bleeding, lead migration, lead fracture, device malfunction, uncomfortable stimulation, loss of benefit, implant site pain, need for reprogramming, battery replacement, revision surgery, nerve irritation, dural puncture headache, rare neurologic injury, incomplete relief, or no relief.
Patients should seek urgent evaluation for fever, wound drainage, spreading redness, severe swelling, new weakness, new numbness, bowel or bladder dysfunction, saddle anesthesia, severe headache after a procedure, chest pain, shortness of breath, severe allergic reaction, rapidly worsening pain, device-related burning or shocking sensation, or new neurological symptoms.
For selected patients, neuromodulation may be an important part of an advanced chronic pain plan. MPM’s role is to determine whether the pain pathway is appropriate, whether the patient is ready for a trial, and how stimulation fits within a coordinated, diagnosis-first care plan.
